← Leaderboards
David Rabuka
Acrigen Biosciences, Inc.
$765,291
Attributed
$765,291
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $256.6K · FY2020–22$500K$375K$250K$125K$0
'20
'21
'22
Funding mix
By agency
NIH$765,291 · 3
By mechanism
R43$508,711 · 2
R41$256,580 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Genes”
- Leonard Freedman · Leidos Biomedical Research, Inc.$97,908,773
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,311,588
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Evan Z Macosko · Broad Institute, Inc.$32,734,698
Research focus
GenesBiological SciencesTextGovernmentEvaluationDesignNucleaseTechnologyClustered Regularly Interspaced Short Palindromic RepeatsGeneticProteinsPersonsGuide RnaHuman DiseaseBiological ModelsAffinityGenomeHuman GenomeGenetic DiseasesClinicBindingGenetic MedicineEffective TherapyCells
Grant awards (3)
Enhancing CRISPR-mediated homology-directed repair using anti-CRISPR proteins$256,580
R43 · FY2022 · GM · contact PI
Development of Safe in Utero Gene Editing Technology in Mice$256,580
R41 · FY2021 · TR · contact PI
Discovery and applications of CRISPR-Cas inhibitor proteins$252,131
R43 · FY2020 · GM · contact PI